Prognostic significance of microvessel density determined by an anti‐CD105/endoglin monoclonal antibody in astrocytic tumors: Comparison with an anti‐CD31 monoclonal antibody

Neuropathology - Tập 25 Số 3 - Trang 201-206 - 2005
Yongxue Yao1, Toshihiko Kubota1, Hiroaki Takeuchi1, Kazufumi Sato1
1Department of Neurosurgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan

Tóm tắt

There are conflicting reports as to whether the degree of angiogenesis as measured by microvessel density (MVD) has a prognostic value in astrocytic tumors. This may be due to the use of different antibodies against endothelial cells to highlight microvessels. It has been reported that unlike pan‐endothelial antibodies, such as CD31, anti‐CD105 antibodies preferentially react with endothelial cells in angiogenic tissues. To clarify the validity of anti‐CD105 antibody in the evaluation of angiogenesis, we assessed MVD using an anti‐CD105 monoclonal antibody (mAb) (CD105‐MVD) and an anti‐CD31 mAb (CD31‐MVD) in a series of 50 astrocytic tumors, and correlated MVD with expression of the key angiogenic factor vascular endothelial growth factor (VEGF) and prognosis. The mean CD31‐MVD and CD105‐MVD was 36.7 and 24.8 for low‐grade astrocytoma (LGA), 48.0 and 42.7 for anaplastic astrocytoma, 55.3 and 51.9 for glioblastoma multiforme (GBM), respectively. CD105‐MVD was more closely correlated with VEGF expression than CD31‐MVD. Patients with LGA and GBM showing higher CD105‐MVD had a significantly shorter mean survival time (MST) than those with lower CD105‐MVD tumors (P = 0.0381 and 0.0131, respectively). Whereas the MST of patients with higher CD31‐MVD tumors seemed to be shorter than that of lower CD31‐MVD patients within each tumor grade, the differences were not statistically significant. These findings suggest that anti‐CD105 mAb may be a better marker than anti‐CD31 mAb in evaluation of angiogenesis and prediction of prognosis in astrocytic tumors.

Từ khóa


Tài liệu tham khảo

Folkman J, 1996, Angiogenesis and tumor growth, N Engl J Med, 334, 921

10.1016/0092-8674(94)90187-2

10.1002/(SICI)1096-9896(199607)179:3<232::AID-PATH505>3.0.CO;2-A

10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z

10.3171/jns.1998.88.3.0513

10.1007/s007010170122

10.1016/S0344-0338(04)70251-4

10.1002/(SICI)1096-9896(199604)178:4<363::AID-PATH491>3.0.CO;2-8

10.1016/S0959-8049(96)00379-6

10.1093/jnci/86.5.386

10.1016/S0021-9258(18)41732-2

10.1096/fasebj.14.1.55

10.1126/science.284.5419.1534

10.1002/ijc.2910540303

Seon BK, 1997, Long‐lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin, Clin Cancer Res, 3, 1031

Kumar S, 1999, Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis, Cancer Res, 59, 856

Tanaka F, 2001, Evaluation of angiogenesis in non‐small cell lung cancer: comparison between anti‐CD34 antibody and anti‐CD105 antibody, Clin Cancer Res, 7, 3410

10.1002/pros.10083

Weidner N, 1993, Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma, Am J Pathol, 143, 401

10.1038/359845a0

10.1023/A:1006499824379

10.1038/sj.bjc.6600315

10.1016/S0002-9440(10)61688-4

Thông tin
Thông tin xuất bản

Neuropathology

Tập 25 Số 3

201-206

Thông tin tác giả